debate 2: braf mutant mcrc patients - clinical trial
Published 9 years ago • 561 plays • Length 13:59Download video MP4
Download video MP3
Similar videos
-
8:27
debate 2: braf mutant mcrc patients - folfirinox/bev
-
4:51
colorectal cancer debate: first line braf v600e - folfoxiri/bev
-
22:40
how to approach the patient with braf mutant tumor
-
11:54
debate: targeted therapy for ras/braf wt left sided colon cancers - bevacizumab or egfr antibodies
-
17:51
how to approach the patient with a braf mutant tumor
-
6:06
colorectal cancer debate: first line braf v600e - targeted triplet
-
20:52
what is the optimal therapy for braf mutant metastatic colorectal cancer?
-
6:22
erbitux for colon cancer
-
4:46
finding the faulty braf gene - cancer research uk
-
58:45
frontiers in oncology: ryan corcoran, md
-
17:17
debate: targeted therapy for ras/braf wt left sided colon cancers - egfr antibodies are mandatory
-
15:52
debate: are novel targets such as her2 ready for prime time in colorectal cancer? - no
-
1:35:47
braf-mutated mcrc: from diagnosis to treatment
-
1:08
ongoing clinical trials in braf-mutant crc
-
2:18
prognosticating braf-mutant mcrc
-
22:10
novel agents and targets in colorectal cancer
-
29:45
keynote lecture 4: the braf pathway in crc?
-
1:09
dr. kopetz on updated data from beacon crc study in braf v600e–mutant crc
-
7:02
triplet regimens in braf-mutant metastatic crc
-
22:46
mutational testing and the treatment of colorectal cancer
-
1:55
dr. lieu on the predictive value of braf v600e mutations in crc